Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Appointed director
Acer Therapeutics Inc. (ACER) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update OLPRUVA™ kits now available in all dosage strengths and ready to ship to patients NEWTON, MA – August 14, 2023 – Acer Therapeutics Inc. , a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. “The second quarter of 2023 marked continued progress for Acer as we execute on our OLPRUVA™ launch strategy,” said Chris Schelling, CEO and Founder of Acer. “We are pleased to offer OLPRUVA™ in the U.S. to certain UCD patients as a novel alternative o..."
06/07/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/15/2023 8-K Quarterly results
Docs: "Acer Therapeutics Reports Q1 2023 Financial Results and Provides Corporate Update U.S. OLPRUVA™ launch progressing ahead of schedule with drug-in-channel now anticipated in mid-June 2023 NEWTON, MA – May 15, 2023 – Acer Therapeutics Inc. , a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update. “The first quarter of 2023 was marked by considerable progress and a number of significant milestones in support of our commercial launch of OLPRUVA™, an innovative treatment option for patients with certain Urea Cycle Disorders ,” said Chris Schellin..."
05/01/2023 8-K Quarterly results
04/27/2023 424B2 Form 424B2 - Prospectus [Rule 424(b)(2)]:
04/27/2023 8-K Quarterly results
04/14/2023 ARS Form ARS - Annual Report to Security Holders:
04/14/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/27/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/27/2023 10-K Annual Report for the period ended December 31, 2022
03/27/2023 8-K Quarterly results
03/23/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/22/2023 8-K Credit agreement amendment
Docs: "Form of Pre-Funded Common Stock Purchase Warrant",
"Form of Common Stock Purchase Warrant",
"Opinion of Pillsbury Winthrop Shaw Pittman LLP",
"Form of Securities Purchase Agreement, between Acer Therapeutics Inc. and the Purchaser",
"Acer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules NEWTON, MA - March 22, 2023 - Acer Therapeutics Inc. , a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced that it has entered into a definitive agreement for the purchase and sale of 2,920,306 shares of the Company's common stock at a purchase price of $0.916 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue warrants to purchase up to 2,920,306 shares of common stock. The warrants will have an exercise price of $0.7..."
03/22/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/17/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Acer Therapeutics Announces Topline Results from ACER-801 Phase 2a Trial ACER-801 safe and well-tolerated but did not achieve statistically significant decrease in frequency or severity of hot flashes in postmenopausal women"
03/15/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Acer Therapeutics Announces Presentation of HCP Urea Cycle Disorder Treatment Preference Data at the Society for Inherited Metabolic Disorders Annual Meeting and Provides OLPRUVA™ Program Update Results to be presented from a survey designed to quantify treatment preferences of healthcare providers for Urea Cycle Disorders"
02/14/2023 SC 13G/A Nantahala Capital Management, LLC reports a 7.5% stake in Acer Therapeutics Inc.
02/13/2023 8-K Quarterly results
02/07/2023 424B2 Form 424B2 - Prospectus [Rule 424(b)(2)]:
02/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Opinion of Pillsbury Winthrop Shaw Pittman LLP",
"Opinion of Pillsbury Winthrop Shaw Pittman LLP"
02/01/2023 8-K Quarterly results
01/31/2023 8-K Credit agreement amendment
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Second Amendment to Credit Agreement dated January 30, 2023, among Acer Therapeutics Inc., the lenders party thereto and SWK Funding LLC, as the agent, sole lead arranger and sole bookrunner",
"Warrant issued on January 30, 2023, by the Company to SWK Funding LLC pursuant to the Second Amendment to Credit Agreement dated January 30, 2023, among Acer Therapeutics Inc., the lenders party thereto and SWK funding LLC, as the agent, sole lead arranger and sole bookrunner",
"Amendment Agreement dated January 30, 2023, with respect to Secured Convertible Note Purchase Agreement between Acer Therapeutics Inc., MAM Aardvark, LLC and Marathon Healthcare Finance Fund, L.P",
"Termination Agreement among Acer Therapeutics Inc., the Lenders party thereto and MAM Aardvark, LLC, not individually, but solely in its capacity as administrative and collateral agent for the Lenders"
01/09/2023 8-K Quarterly results
01/05/2023 8-K Investor presentation
Docs: "Acer Therapeutics Inc. Corporate Presentation, January 2023",
"Acer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 in Men with Adenocarcinoma of the Prostate POSH-MAP and PORT-MAP investigator-sponsored trials to evaluate ability of ACER-801 to reduce hot flashes and as neoadjuvant therapy in men with prostate cancer"
01/03/2023 8-K Investor presentation
Docs: "Extension Agreement, among Acer Therapeutics Inc., MAM Aardvark, LLC as administrative and collateral agent for the lenders, and the lenders party thereto",
"Acer Therapeutics Inc. Corporate Presentation, January 2023"
12/29/2022 8-K Quarterly results
12/27/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders New FDA-approved formulation for patients living with urea cycle disorders"
12/08/2022 8-K Quarterly results
12/02/2022 D Form D - Notice of Exempt Offering of Securities:
12/02/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
11/30/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy